{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:15:09Z","timestamp":1793391309361,"version":"4.5.0"},"reference-count":78,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,17]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy that may result in major bleeding events and reduction of chemotherapy relative dose intensity. Although there remain no widely available licensed therapies to manage CIT, major studies, including global pivotal phase 3 clinical trials of the thrombopoietin receptor agonists (TPO-RAs) romiplostim and avatrombopag in CIT, have been completed, along with additional supporting evidence from other clinical trials and observational studies. As with patients with chemotherapy-induced neutropenia, not all patients with CIT require treatment, but for those who do, it can have a major impact on a patient\u2019s oncologic care and outcomes. Proper management of CIT requires an understanding of the 2 clinical subtypes of CIT (persistent and nadir), the limited role of platelet transfusions and antifibrinolytics, and when and how to appropriately use TPO-RA support. In this article, 4 patient cases of CIT are used to illustrate common and challenging scenarios occurring in clinical practice. Built on a framework of published studies and supported by extensive clinical experience, appropriate treatment strategies for CIT are described in detail, with emphasis on proper selection of patient, dosing, titration, and monitoring for the use of TPO-RAs in CIT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026034099","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:24:55Z","timestamp":1783358695000},"page":"1534-1546","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[{"name":"1Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald A.","family":"Soff","sequence":"additional","affiliation":[{"name":"3Division of Hematology, University of Miami\/Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2026091711212752900_bib1","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","article-title":"Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors","volume":"37","author":"Epstein","year":"2020","journal-title":"Adv Ther"},{"key":"2026091711212752900_bib2","unstructured":"National Comprehensive Cancer Network. Hematopoietic Growth Factors. Accessed 15 March 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493."},{"issue":"Pt 2","key":"2026091711212752900_bib3","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007","volume":"31","author":"Wu","year":"2009","journal-title":"Clin Ther"},{"issue":"5","key":"2026091711212752900_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2026091711212752900_bib5","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"2026091711212752900_bib6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/09537104.2022.2117293","article-title":"Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies","volume":"33","author":"Cheloff","year":"2022","journal-title":"Platelets"},{"issue":"4","key":"2026091711212752900_bib7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia","volume":"19","author":"Elting","year":"2001","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026091711212752900_bib8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A no-prophylaxis platelet-transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"2026091711212752900_bib9","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/trf.17569","article-title":"Lower platelet count and metastatic tumor are associated with increased risk of spontaneous bleeding in critically ill patients with cancer: An observational study","volume":"63","author":"Kayano","year":"2023","journal-title":"Transfusion"},{"issue":"6","key":"2026091711212752900_bib10","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3324\/haematol.2023.284192","article-title":"Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer","volume":"109","author":"Patell","year":"2024","journal-title":"Haematologica"},{"issue":"22","key":"2026091711212752900_bib11","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy","volume":"3","author":"Al-Samkari","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2026091711212752900_bib12","first-page":"6S8","article-title":"Cancer and thrombosis: new insights to an old problem","volume":"45","author":"Leiva","year":"2020","journal-title":"J Med Vasc"},{"issue":"5","key":"2026091711212752900_bib13","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/1078155219880255","article-title":"Polypharmacy and comorbidities among ambulatory cancer patients: a cross-sectional retrospective study","volume":"26","author":"Alwhaibi","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"2026091711212752900_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.joim.2025.10.004","article-title":"Potential supplement-drug interactions and bleeding in patients with cancer: a UK Biobank study","volume":"24","author":"Lam","year":"2026","journal-title":"J Integr Med"},{"issue":"2","key":"2026091711212752900_bib15","first-page":"925","article-title":"Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer","volume":"28","author":"Crawford","year":"2020","journal-title":"Support Care Cancer"},{"issue":"24","key":"2026091711212752900_bib16","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","article-title":"Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices","volume":"21","author":"Lyman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"21","key":"2026091711212752900_bib17","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026091711212752900_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10549-018-4906-8","article-title":"Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)","volume":"172","author":"Claessens","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2026091711212752900_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2026091711212752900_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","article-title":"A review of relative dose intensity and survival in patients with metastatic solid tumors","volume":"93","author":"Havrilesky","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2026091711212752900_bib21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-014-2416-x","article-title":"The impact of dose\/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer","volume":"73","author":"Nakayama","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2026091711212752900_bib22","doi-asserted-by":"crossref","first-page":"e1609","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"issue":"10","key":"2026091711212752900_bib23","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","article-title":"The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Lyman","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"2026091711212752900_bib24","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","article-title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","volume":"29","author":"Lyman","year":"2018","journal-title":"Ann Oncol"},{"issue":"31","key":"2026091711212752900_bib25","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026091711212752900_bib26","doi-asserted-by":"crossref","first-page":"e12701","DOI":"10.1002\/rth2.12701","article-title":"Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use","volume":"6","author":"Wilkins","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2026091711212752900_bib27","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2026091711212752900_bib28","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.3324\/haematol.2017.180166","article-title":"The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"103","author":"Al-Samkari","year":"2018","journal-title":"Haematologica"},{"issue":"15","key":"2026091711212752900_bib29","doi-asserted-by":"crossref","first-page":"e7429","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy-induced thrombocytopenia: a review of the literature","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med"},{"issue":"11","key":"2026091711212752900_bib30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMoa2511882","article-title":"Romiplostim versus placebo for chemotherapy-induced thrombocytopenia","volume":"394","author":"Al-Samkari","year":"2026","journal-title":"N Engl J Med"},{"issue":"1","key":"2026091711212752900_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH subcommittee on hemostasis and malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026091711212752900_bib32","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026091711212752900_bib33","article-title":"Avatrombopag versus placebo for persistent chemotherapy-induced thrombocytopenia in gastrointestinal cancers: the phase II ACT-GI trial","author":"Al-Samkari","year":"13  2026","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026091711212752900_bib34","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2025031449","article-title":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors","volume":"147","author":"Leaf","year":"2026","journal-title":"Blood"},{"issue":"1","key":"2026091711212752900_bib35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/hematology.2022000374","article-title":"Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem","volume":"2022","author":"Al-Samkari","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2026091711212752900_bib36","doi-asserted-by":"crossref","first-page":"101139","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists","volume":"63","author":"Al-Samkari","year":"2024","journal-title":"Blood Rev"},{"issue":"8","key":"2026091711212752900_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/curroncol32080455","article-title":"Understanding chemotherapy-induced thrombocytopenia: implications for gastrointestinal cancer treatment","volume":"32","author":"Peshin","year":"2025","journal-title":"Curr Oncol"},{"issue":"5","key":"2026091711212752900_bib38","doi-asserted-by":"crossref","first-page":"102980","DOI":"10.1016\/j.rpth.2025.102980","article-title":"Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?","volume":"9","author":"Al-Samkari","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2026091711212752900_bib39","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment","volume":"206","author":"Song","year":"2025","journal-title":"Br J Haematol"},{"issue":"3","key":"2026091711212752900_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026091711212752900_bib41","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.2022016308","article-title":"Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial","volume":"140","author":"Gernsheimer","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026091711212752900_bib42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtha.2025.09.009","article-title":"Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis","volume":"24","author":"Alsuliman","year":"2026","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2026091711212752900_bib43","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/jth.14295","article-title":"Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease","volume":"16","author":"Michelson","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2026091711212752900_bib44","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/blood-2011-11-393900","article-title":"In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation","volume":"119","author":"Psaila","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2026091711212752900_bib45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00277-018-3556-6","article-title":"Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim","volume":"98","author":"Al-Samkari","year":"2019","journal-title":"Ann Hematol"},{"issue":"2","key":"2026091711212752900_bib46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V88.2.511.bloodjournal882511","article-title":"Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates","volume":"88","author":"Harker","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2026091711212752900_bib47","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.V87.5.1833.1833","article-title":"Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates","volume":"87","author":"Harker","year":"1996","journal-title":"Blood"},{"issue":"3","key":"2026091711212752900_bib48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0039-1700512","article-title":"Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment","volume":"46","author":"Al-Samkari","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"2026091711212752900_bib49","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/ajh.26338","article-title":"Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia","volume":"96","author":"Song","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"2026091711212752900_bib50","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"Kellum","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2026091711212752900_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cam4.326","article-title":"Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study","volume":"4","author":"Winer","year":"2015","journal-title":"Cancer Med"},{"issue":"6","key":"2026091711212752900_bib52","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int J Hematol"},{"issue":"1","key":"2026091711212752900_bib53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.19861","article-title":"A second chance for avatrombopag in chemotherapy-induced thrombocytopenia","volume":"206","author":"Al-Samkari","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"2026091711212752900_bib54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00280-011-1679-8","article-title":"Hematologic adverse events associated with temozolomide","volume":"69","author":"Villano","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2026091711212752900_bib55","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/neuonc\/noab240","article-title":"Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies","volume":"24","author":"Park","year":"2022","journal-title":"Neuro Oncol"},{"issue":"8","key":"2026091711212752900_bib56","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/bloodadvances.2022007838","article-title":"Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026091711212752900_bib57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/cancers18020188","article-title":"Romiplostim for prevention of severe chemotherapy-induced thrombocytopenia in lymphoma patients-phase I study","volume":"18","author":"Joffe","year":"2026","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2026091711212752900_bib58","doi-asserted-by":"crossref","first-page":"e31977","DOI":"10.1002\/pbc.31977","article-title":"A single institutional experience using romiplostim to treat therapy-related thrombocytopenia in pediatric solid tumor patients","volume":"72","author":"Degliuomini","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2026091711212752900_bib59","doi-asserted-by":"crossref","first-page":"e32011","DOI":"10.1002\/pbc.32011","article-title":"Romiplostim for chemotherapy-induced thrombocytopenia: a case cohort assessment of safety, efficacy, and proposed future study in pediatric patients with solid tumors","volume":"72","author":"Gorfinkel","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2026091711212752900_bib60","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"2026091711212752900_bib61","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"2026091711212752900_bib62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/1471-2407-12-405","article-title":"Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors","volume":"12","author":"Erickson-Miller","year":"2012","journal-title":"BMC Cancer"},{"key":"2026091711212752900_bib63","doi-asserted-by":"crossref","first-page":"135354","DOI":"10.1155\/2010\/135354","article-title":"Thrombopoietin receptor levels in tumor cell lines and primary tumors","volume":"2010","author":"Erickson-Miller","year":"2010","journal-title":"J Oncol"},{"issue":"5","key":"2026091711212752900_bib64","first-page":"e350","article-title":"The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy","volume":"4","author":"Liao","year":"2023","journal-title":"Med Comm (2020)"},{"issue":"9","key":"2026091711212752900_bib65","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41416-024-02630-w","article-title":"Risk and adverse clinical outcomes of thrombocytopenia among patients with solid tumors-a Danish population-based cohort study","volume":"130","author":"Adelborg","year":"2024","journal-title":"Br J Cancer"},{"issue":"12","key":"2026091711212752900_bib66","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/ajh.25275","article-title":"Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia","volume":"93","author":"Al-Samkari","year":"2018","journal-title":"Am J Hematol"},{"issue":"11","key":"2026091711212752900_bib67","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1358\/dot.2018.54.11.2899441","article-title":"Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease","volume":"54","author":"Al-Samkari","year":"2018","journal-title":"Drugs Today (Barc)"},{"issue":"12","key":"2026091711212752900_bib68","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.23562","article-title":"Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists","volume":"88","author":"Makar","year":"2013","journal-title":"Am J Hematol"},{"issue":"7","key":"2026091711212752900_bib69","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CJI.0000000000000428","article-title":"Pembrolizumab-induced acquired amegakaryocytic thrombocytopenia and successful combination treatment with eltrombopag, romiplostim and cyclosporine: a brief communication","volume":"45","author":"Park","year":"2022","journal-title":"J Immunother"},{"key":"2026091711212752900_bib70","doi-asserted-by":"crossref","first-page":"2040620719837906","DOI":"10.1177\/2040620719837906","article-title":"Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia","volume":"10","author":"Gonzalez-Porras","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"2026091711212752900_bib71","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study","volume":"197","author":"Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2026091711212752900_bib72","doi-asserted-by":"crossref","first-page":"100134","DOI":"10.1016\/j.rpth.2023.100134","article-title":"Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia","volume":"7","author":"Al-Samkari","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"2026091711212752900_bib73","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood.V95.8.2530","article-title":"A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia","volume":"95","author":"Schiffer","year":"2000","journal-title":"Blood"},{"issue":"25","key":"2026091711212752900_bib74","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","article-title":"Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia","volume":"132","author":"Dickinson","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2026091711212752900_bib75","first-page":"1405","article-title":"Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells","volume":"10","author":"Drexler","year":"1996","journal-title":"Leukemia"},{"issue":"18","key":"2026091711212752900_bib76","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-04-219493","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"114","author":"Will","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2026091711212752900_bib77","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.25545","article-title":"Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"issue":"12","key":"2026091711212752900_bib78","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40265-019-01159-0","article-title":"Eltrombopag in immune thrombocytopenia, aplastic Anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation","volume":"79","author":"Fattizzo","year":"2019","journal-title":"Drugs"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/12\/1534\/2588610\/blood_bld-2026-034099-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/12\/1534\/2588610\/blood_bld-2026-034099-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:21:42Z","timestamp":1789658502000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/12\/1534\/569575\/How-I-treat-chemotherapy-induced-thrombocytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":78,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026034099","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,17]]},"published":{"date-parts":[[2026,9,17]]}}}